z-logo
open-access-imgOpen Access
Sodium Caseinate in Combination With Daunorubicin or Cytarabine Improves Survival of Mice With Long-established Leukemia
Author(s) -
Itzen Aguíñiga-Sánchez,
Edgar Ledesma-Martínez,
José Luis Lara-Castañeda,
Frida Montserrat Meléndez-Ibarra,
Benny WeissSteider,
Isabel SotoCruz,
Guadalupe R. Fajardo-Orduña,
Edelmiro SantiagoOsorio
Publication year - 2022
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10133
Subject(s) - daunorubicin , cytarabine , leukemia , bone marrow , myeloid leukemia , medicine , immunology , pharmacology
Although acute myeloid leukemia (AML) has traditionally been considered an oncological emergency and initiation of therapy is believed to be crucial to minimizing disease-related morbidity and mortality, it has also been suggested that a certain delay in treatment has no negative consequences in terms of response, early mortality, or survival. We aimed to determine the effect of administration of sodium caseinate (SC), a salt of casein, the main milk protein, with cytarabine or with daunorubicin on survival in mice with well-established leukemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom